The transcription factor activator protein 2 (AP-2) gene is a possible candidate gene for schizophrenia, since it maps near D6S470, a marker on chromosome 6p24 that provided evidence of linkage to schizophrenia. In the present study we analyzed the promoter region and the whole coding region of the human AP-2 gene in order to identify genetic variations that may lead to the modification of AP-2 expression or the alteration of protein function, contributing to schizophrenia or particular schizophrenic phenotypes. Genomic DNA was isolated from the whole blood samples of 87 unrelated schizophrenics and 100 healthy controls. Polymerase chain reaction (PCR) was performed, using 15 primer sets that spanned the promoter region and the whole coding region, and amplified products were screened by single-strand conformational polymorphism (SSCP) analysis. Aberrant SSCP patterns were analyzed by direct sequencing. Three novel polymorphisms were found in the promoter region; two relatively common (Ϫ90GAEC, Ϫ803GAET) and one rare (Ϫ1769GAEA). Polymorphic status at both loci suggested strong linkage disequilibrium between the Ϫ90G and Ϫ803G alleles, and between the Ϫ90C and Ϫ803T alleles. Although no significant differences in genotypic and allelic frequencies at the Ϫ90 and Ϫ803 loci were found between patients and controls, significant differences in the distribution of genotypes at the Ϫ90 (P ϭ 0.008) and Ϫ803 (P ϭ 0.037) loci were observed in patients with an episodic course compared with controls. However, the difference for the Ϫ803 locus was not significant after Bonferroni correction for multiple comparisons. Our data provided no direct evidence of an association between schizophrenia and the polymorphisms of the AP-2 gene, although the positive result at the Ϫ90 locus J Hum
Introduction
Schizophrenia is thought to be a multifactorial disease. Twin, family, and adoption studies have consistently revealed that genetic factors are involved in this disease (Gottesman 1994) . A number of recent linkage studies have suggested the presence of schizophrenia susceptibility loci on chromosome 6p24-21 (Antonarakis et al. 1995; Moises et al. 1995; Schwab et al. 1995; Straub et al. 1995; Wang et al. 1995; Schizophrenia Linkage Collaborative Group for Chromosomes 3, 6 and 8 1996) . Integrated physical maps of this region have been constructed to facilitate the identification of candidate genes for schizophrenia, and a large number of genes have been mapped Olavesen et al. 1995; Olavesen et al. 1997) . Studies of the spinocerebellar ataxia type 1 (SCA1) gene, mapped to chromosome 6p23, were not consistent with regard to its association with schizophrenia (Wang et al. 1996; MorrisRosendahl et al. 1997) . As the chromosomal markers spanned a relatively wide region on the short arm of chromosome 6, further studies of this region are required to investigate other candidate genes involved in schizophrenia.
The transcription factor activator protein 2 (AP-2) gene may be a possible candidate gene for schizophrenia, as it mapped near the marker, D6S470, on chromosome 6p24 Olavesen et al. 1997 ) that provided evidence of linkage to schizophrenia (Schwab et al. 1995; Straub et al. 1995) . AP-2 regulates the expression of genes required for the development of tissues of ectodermal origin, such as neural crest, brain, and skin (Mitchell et al. 1991; Williams and Tjian 1991a,b) . AP-2 binds as a Novel polymorphisms of the AP-2 gene (6p24): Analysis of association with schizophrenia homodimer to the consensus recognition sequence GCCNNNGGC, which is an important cis-regulatory element for a variety of genes, including proenkephalin (Hyman et al. 1989 ), presenilin-2 (Pennypacker et al. 1998 ), 1 -adrenergic receptor (Okawa et al. 1998) , synapsin II (Petersohn et al. 1995) , α3 nicotinic receptor subunit (Fornasari et al. 1997) , dopamine D1 receptor (Minowa et al. 1992) , dopamine -hydroxylase (Kim et al. 1998) , phenylethanolamine N-methyltransferase (Ebert et al. 1998) , metallothionein II A (Imagawa et al. 1987) , keratin (Leask et al. 1991) , and AP-2 (Bauer et al. 1994) .
The modification of AP-2 expression or the alteration of protein function due to mutations of the AP-2 gene may contribute to susceptibility to schizophrenia. In this study, we investigated genetic variations in the promoter region and the coding region of the human AP-2 gene. We also conducted a case-control study to explore the association between polymorphisms in the AP-2 gene and schizophrenia, including the subtypes and course specifiers in the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV (American Psychiatric Association 1994).
Materials and methods

DNA samples
Written informed consent, according to research protocols approved by the Ethics Committee of Tsukuba University, was obtained from 87 unrelated schizophrenics consisting of 53 men (mean age, 46.3 Ϯ 12.7 years; mean age at onset, 25.7 Ϯ 7.6 years) and 34 women (mean age, 47.3 Ϯ 16.3 years; mean age at onset, 27.7 Ϯ 10.7 years) who met the DSM-IV criteria for schizophrenia (American Psychiatric Association, 1994) . The subtype and course specifier for each patient had been determined with the DSM-IV before the genomic DNA analysis in this study was performed.
The controls consisted of 100 unrelated healthy volunteers (30 men; mean age, 32.1 Ϯ 11.4 years and 70 women; mean age, 43.1 Ϯ 12.0 years) who were hospital employees living in the same area as the patients. All patients and controls were ethnically Japanese. Genomic DNA was prepared from whole blood samples collected in disodium ethylenediaminetetraacetic acid (EDTA; 3mg/l). Genomic DNA was extracted by the sodium iodide method (DNA Extractor WB Kit; Wako Pure Chemical Industries, Tokyo, Japan).
Polymerase chain reaction (PCR) conditions
The nucleotide sequence and the genomic structure of the human AP-2 gene have been reported previously, and the nucleotide sequence numbering used in this study was based on that in a previous report (Bauer et al. 1994 ). The mature AP-2 mRNA is spliced from seven exons distributed over a region of 18 kb of genomic DNA, and an inhibitory AP-2 protein, designated AP-2B, is generated by alternative usage after the fifth exon (Bauer et al. 1994 ).
The promoter of the AP-2 gene contains three AP-2 binding sites (nucleotides Ϫ622 to Ϫ614, Ϫ425 to Ϫ417, Ϫ385 to Ϫ378), an NF-1 binding site (nucleotides Ϫ365 to Ϫ353), an octamer binding site (nucleotides Ϫ339 to Ϫ330), a CT-rich repetitive element (nucleotides Ϫ240 to Ϫ103) (Bauer et al. 1994; Creaser et al. 1996) , and a potential binding site for transcription factor NF-kB (nucleotides Ϫ1827 to Ϫ1818) (Baeuerle 1991) . Fifteen sets of PCR primers were prepared to produce fragments covering these motifs and the CT-rich repetitive element in the promoter region, and the whole coding region, including the AP-2B-specific region, and all of the exon-intron boundaries of the AP-2 gene ( Table 1 ). The 5Ј-terminus of each primer, except for the AP2STRPR primer, was labeled with indodicarbocyanine fluorescent dye (Pharmacia Biotech, Uppsala, Sweden) to perform fluorescence-based single-strand conformational polymorphism (SSCP) analysis. PCR was performed as reported previously (Kawanishi et al. 1998) , with a minor modification: demethyl sulfoxide (final concentration, 5%) was added to the PCR reaction mixture for two primers sets; AP2PMF and AP2PMR, and AP2EX4PF and AP2EX4PR primers.
Single-strand conformational polymorphism (SSCP) analysis
Fluorescence-based SSCP analysis was performed as reported previously (Kawanishi et al. 1998) , with slight modifications. Polyacrylamide gels (PAG) used were 7% (49: 1, acrylamide: bisacrylamide ratio) or 10% (99: 1, acrylamide: bisacrylamide ratio) containing 0.5ϫ Tris-Borate-EDTA buffer, or 7% (49 : 1, acrylamide: bisacrylamide ratio) containing 0.5ϫ Tris-Borate-EDTA buffer and 10% glycerol.
PCR product sequencing PCR products showing altered band patterns by SSCP analysis were purified by centrifugation, using Microcon tubes (Amicon, Danver, MA, USA). DNA sequences of PCR products were directly determined from both directions, using a cycle sequencing system (Dye Terminator Cycle Sequencing Ready Reaction and ABI PRISM 310 Genetic Analyzer; Perkin-Elmer, Norwalk, Conn, USA).
Restriction enzyme assay
Restriction fragment-length polymorphism (RFLP) analysis was performed, using a commercially available restriction enzyme according to the manufacturer's recommendations (NIPPON GENE, Tokyo, Japan). Digested products were visualized by electrophoresis in 2% agarose gels after ethidium bromide staining.
Statistical analysis
Deviation of the genotype counts from Hardy-Weinberg equilibrium was tested using 2 test for goodness of fit.
Significant differences in genotypic frequencies between patients and controls were analyzed using the 2 test (2 ϫ 3 table) for independence at a significance level of 0.05 (twotailed). Significant differences in allelic frequencies between patients and controls were analyzed by Fisher's exact test (2 ϫ 2 table). Bonferroni correction for multiple comparisons was carried out to exclude type I error. Analysis of linkage disequilibrium was performed with an Associate program (version 2.32) in the Linkage Utility programs (Terwilliger and Ott 1994) .
Results
Three variants in the promoter region of the AP-2 gene were identified by SSCP analysis, followed by sequencing. The first variant that showed as an altered SSCP banding pattern was characterized by a single base pair substitution (GAEC) at nucleotide position Ϫ90 by sequencing. The presence of a Ϫ90GAEC nucleotide substitution was confirmed by RFLP analysis using Msp I. Figure 1 shows the SSCP analysis, sequencing, and RFLP analysis for the Ϫ90GAEC variant. The second variant was characterized by a single base pair substitution (GAET) at nucleotide position Ϫ803 (Fig. 2) . No restriction enzyme was commercially available to allow RFLP analysis of the Ϫ803GAET variant. The third variant was characterized by a single base pair substitution (GAEA) at nucleotide position Ϫ1769, which was found as a heterozygote in a single control sample. However, no variant was identified in the whole coding region, or in any of the exonintron boundaries of the AP-2 gene.
Contrary to previously published sequence data (Bauer et al. 1994) , inconsistencies, i.e., the C nucleotide insertion between nucleotides Ϫ89 and Ϫ88 (see Fig. 1 ), the G nucleotide insertion between nucleotides Ϫ807 and Ϫ806, and the G instead of C at nucleotide position Ϫ808 (see Fig. 2) were observed in all samples tested. Table 2 indicates polymorphic status between the Ϫ90 and Ϫ803 loci in schizophrenics and controls. The polymorphic status of each sample at these two loci was almost identical, and suggested that strong, but not complete, linkage disequilibrium had occurred between the Ϫ90G and Ϫ803G alleles, and between the Ϫ90C and Ϫ803T alleles. Table 3 shows the genotypic and allelic frequencies at the AP-2 Ϫ90 and Ϫ803 loci in schizophrenics, including subtypes and course specifiers, and controls. Deviation from Hardy-Weinberg equilibrium was tested for each of the groups. Evidence of significant deviation was obtained in schizophrenics with a continuous course ( 2 ϭ 4.05; degree of freedom [df] ϭ 1; P ϭ 0.044). This probably results from the relatively small population samples. No significant deviation was observed in other groups. No significant differences in genotypic and allelic frequencies at the Ϫ90 and PCR, Polymerase chain reaction Ϫ803 loci were found between patients and controls. The limited size of the patient sample presented a problem for the statistical analysis. Because the frequency of the expected values smaller than 5 was more than 20%, a complete anaysis of each of the individual subtypes and course specifiers within the patient group was not possible. For the purpose of the analysis, therefore the catatonic subtype and the undifferentiated subtype were grouped into a single category. The same was done for the patients in the single episode and other or unspecified pattern. No association was observed between the genotypic and allelic distributions, and the subtypes of schizophrenia. In regard to course specifiers, there was a significant difference in the distribution of genotypes at the Ϫ90 locus between patients with an episodic course and controls ( 2 ϭ 9.56; df ϭ 2; P ϭ 0.008; and P ϭ 0.016 after Bonferroni correction). There was also a significant difference in the distribution of genotypes at the Ϫ803 locus between patients with the episodic course and controls ( 2 ϭ 6.60; df ϭ 2; P ϭ 0.037), but the observed P value was 0.074 after Bonferroni correction. No significant differences in allelic frequencies at the loci were found between the groups. Delta value ϭ 0.2107; 2 ϭ 159.198; df ϭ 1; P Ͻ 0.000001 Fig. 1 . Single-strand conformational polymorphism (SSCP) analysis, direct sequencing, and restriction fragment-length polymorphism (RFLP) analysis of polymerase chain reaction (PCR) products generated using the AP2STRPF and AP2STRPR primer sets. Shown here is reverse sequencing. A single base pair substitution (GAEC) at nucleotide position Ϫ90 was detected by sequencing (S ϭ C or G). A C nucleotide insertion between nucleotides Ϫ89 and Ϫ88 was observed in all samples, contrary to previously published sequence data. In the absence of the mutated site, the 322-bp PCR product was cut by Msp I, producing fragments of 195 and 127 bp. Samples 1, 2, and 3 indicate homozygous (G/G), heterozygous (G/C), and homozygous (C/C) Ϫ90 locus genotypes, respectively
Discussion
Three polymorphisms were found in the promoter region, two relatively common (Ϫ90GAEC, Ϫ803GAET) and one rare (Ϫ1769GAEA). Polymorphic status at both loci suggested strong linkage disequilibrium between the Ϫ90 and Ϫ803 loci. This may be the first report of nucleotide sequence variants of the human AP-2 gene. However, none of the three nucleotide variants reported in this study corresponded to the motifs relating to transcriptional regulation of the AP-2 gene. This suggests that the variants are not likely to have functional influence on the transcriptional activity of the AP-2 gene. Fig. 2 . SSCP analysis and direct sequencing of PCR products generated using the AP2PMF and AP2PMR primer sets. A single base pair substitution (GAET) at nucleotide position Ϫ803 was detected by sequencing (K ϭ G or T). Samples 1, 2, and 3 indicate homozygous (G/G), heterozygous (G/T), and homozygous (T/ T) Ϫ803 locus genotypes, respectively. A G nucleotide insertion between nucleotides Ϫ807 and Ϫ806, and a G instead of C at nucleotide position Ϫ808 were observed in all samples, contrary to previously published sequence data Table 3 . Genotypic and allelic frequencies at the AP-2 Ϫ90 and Ϫ803 loci in schizophrenics, including subtypes and course specifiers (American Psychiatric Association 1994), and controls
Schizophrenics ( (18) 11 (61) 5 (28) 2 (11) 27 (75) 9 (25) 11 (61) 5 (28) 2 (11) 27 (75) 9 (25) 2 ϭ 3.41, P ϭ 0.181 P ϭ 0.556 2 ϭ 2.80, P ϭ 0.247 P ϭ 0.556 Disorganized type (28) 7 (25) 16 (57) 5 (18) 30 (54) 26 (46) 7 (25) 16 (57) 5 (18) 30 (54) (13) 2 ϭ 1.54, P ϭ 0.463 P ϭ 0.507 2 ϭ 1.30, P ϭ 0.523 P ϭ 0.824 Residual type (28) 12 (43) 12 (43) 4 (14) 36 (64) 20 (36) 12 (43) 13 (46) 3 (11) 37 (66) 19 (34) 2 ϭ 2.22, P ϭ 0.330 P ϭ 0.628 2 ϭ 0.423, P ϭ 0.810
Episodic (53) 21 (39) 20 (38) 12 (23) 62 (58) 44 (42) 22 (41) 20 (38) 11 (21) 64 (60) (15) 2 ϭ 0.098, P ϭ 0.952 P ϭ 1.000 2 ϭ 0.038, P ϭ 0.981 P ϭ 1.000 Controls (100) 43 (43) 51 (51) 6 (6) 137 (69) 63 (31) 44 (44) 49 (49) 7 (7) 137 (69) 63 (31) The whole coding region containing the AP-2B specific region, and all of the exon-intron boundaries of the AP-2 gene were analyzed in order to identify genetic variations that may lead to the alteration of protein function. However, no variant was detected in these coding regions. This suggests that the sequence in the coding region of the AP-2 gene may be well conserved, or that a severe phenotype may be expected from the alteration of protein function due to mutations of the AP-2 gene, as is seen for the CREB binding protein (CBP) in Rubinstein-Taybi syndrome (Petrij et al. 1995) . However, it is possible that we missed a variant, as the sensitivity of SSCP analysis is not believed to be 100% (Hayashi 1992; Jordanova et al. 1997) .
No significant differences in genotypic and allelic frequencies at the Ϫ90 and Ϫ803 loci were found between patients and controls. Significant differences in the distribution of genotypes at the Ϫ90 and Ϫ803 loci were observed in patients with an episodic course compared with controls, although no significant differences in allelic frequencies were observed between the groups. The observed P value for the distribution of genotypes in patients with an episodic course showed siginificance with regard to the -90 locus after the Bonferroni correction for multiple comparisons. In contrast, a type I error may be involved in the positive result of the -803 locus, since the observed P value showed no significance after the Bonferroni correction. Our small number of samples may have led to a discrepancy between the results of statistical analysis of the -90 and -803 loci with strong linkage disequilibrium and to a discrepancy between the results of statistical analysis of genotypic and allelic frequencies at the Ϫ90 locus. A substantially larger sample size may clarify these inconsistencies.
Recent studies have suggested that functional polymorphisms in the promoter regions of genes expressed in the brain are involved in the susceptibility to neuropsychiatric disorders, including schizophrenia, affective disorder, panic disorder, and Alzheimer's disease (Collier et al. 1996; Arinami et al. 1997; Artiga et al. 1998; Ohara et al. 1998; Wang et al. 1998) . Considering the many genes that contain AP-2 binding sites, the widespread roles of AP-2, and the profound developmental abnormalities observed in AP-2 null mice (Schorle et al. 1996; Zhang et al. 1996) , it is possible that variants located not in the coding region but in the promoter region of the AP-2 gene, which may exert a subtle effect on AP-2 protein expression, could be involved in the development of particular schizophrenic phenotypes.
In conclusion, our data provided no direct evidence of an association between schizophrenia and the polymorphisms of the AP-2 gene, although the positive result at the Ϫ90 locus in schizophrenics with an episodic course is potentially interesting. Therefore, a follow-up study with a large sample size will be necessary to determine whether there is significant statistical evidence for involvement of the AP-2 gene in susceptibility to schizophrenia. The polymorphic site did not correspond to any putative consensus sequences of transcriptional factors reported previously, but we can not exclude the possibility that this polymorphic site may be involved in the binding cis-elements of unknown transcriptional factors. Further detailed analysis will be necessary to support the notion that the transversion from Ϫ90 G to C changes the transcriptional activity of the AP-2 gene. These analyses are being carried out in our laboratory.
